PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Monovo 1 mg/g ointment. Mometasone furoate

Similar documents
PACKAGE LEAFLET 1 April 2017

Package leaflet: Information for the patient. Mometasone furoate 0.1%w/w Ointment (mometasone furoate)

Package leaflet: Information for the user. Monovo 1 mg/g cutaneous emulsion. mometasone furoate

Patient Leaflet : Information for the user Locoid Cream 0.1% w/w Hydrocortisone butyrate

Package leaflet: Information for the user. Fluticrem 0.05% cream Fluticasone propionate

Package leaflet: Information for the user

Hydrocortisyl Skin Cream 1% Hydrocortisone

Package leaflet: Information for the user. PRED MILD STERILE OPHTHALMIC SUSPENSION 0.12% w/v Eye Drops, Suspension Prednisolone Acetate

Package leaflet: Information for the patient. Xemacort 20 mg/g + 1 mg/g cream (fusidic acid and betamethasone)

1.3.1 PACKAGE LEAFLET: INFORMATION FOR THE USER

Cutivate 0.05% w/w Cream fluticasone propionate

Package leaflet: Information for the user. CLARELUX 500 microgram/g cutaneous foam in pressurised container (Clobetasol propionate)

Package leaflet: Information for the patient. Eczibet 20 mg/g + 1 mg/g cream (fusidic acid and betamethasone)

1. WHAT IS CANESTEN HC CREAM AND WHAT IS IT USED FOR?

Package leaflet: Information for the user. Relestat, 0.5 mg/ml, eye drops, solution Epinastine hydrochloride

Package leaflet: Information for the patient. IKERVIS 1 mg/ml, eye drops, emulsion ciclosporin

NOVASONE Mometasone furoate

Package Leaflet: Information for the user. LUMIGAN 0.3 mg/ml, eye drops, solution, in single-dose container Bimatoprost

Proctosedyl Ointment Hydrocortisone/Cinchocaine hydrochloride/framycetin sulphate/aesculin

Unofficial translation of the German package leaflet. Package leaflet: Information for the user

Package leaflet: Information for the user. Carmellose sodium

Zatamil Mometasone furoate 0.1% w/w

Package leaflet: Information for the user. NEVANAC 1 mg/ml eye drops, suspension Nepafenac

PRED FORTE 1% w/v Eye Drops, Suspension Prednisolone acetate

Package leaflet: Information for the user. Zoviduo 50 mg/g and 10 mg/g cream. Aciclovir and Hydrocortisone

Package leaflet: Information for the patient

Package leaflet: Information for the patient. Verkazia 1 mg/ml eye drops emulsion ciclosporin

Package leaflet: Information for the User Clarityn 1 mg/ml syrup Loratadine

Betnovate RD (ready diluted) 0.025% w/w Cream betamethasone (as valerate)

Package leaflet: Information for the patient. Brimonidine Biogaran 2 mg/ml eye drops, solution. brimonidine tartrate

PACKAGE LEAFLET: INFORMATION FOR THE USER Clotrimazole Cream 1%

PACKAGE LEAFLET: INFORMATION FOR THE USER ACULAR 0.5% w/v EYE DROPS, SOLUTION (Ketorolac trometamol)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Flutarzole 0,05% w/w cream, Fluticasone propionate

Package leaflet: Information for the user Oftaquix 5 mg/ml eye drops, solution. Levofloxacin

Package leaflet: Information for the patient

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Beclometasone dipropionate

Package Leaflet: Information for the user. NEVANAC 3 mg/ml eye drops, suspension nepafenac

Package leaflet: Information for the user. Zidoval 7.5 mg/g Vaginal Gel Metronidazole

Package leaflet: Information for the User Clarityn 10 mg tablets Loratadine

PATIENT INFORMATION LEAFLET. Urea 10% w/w Cream

PACKAGE LEAFLET: INFORMATION FOR THE USER. Tacrolimus 0.1% Ointment Tacrolimus

Package leaflet: Information for the patient. Histaclar 10 mg Film-coated Tablets loratadine

ANBESOL TM Anaesthetic Antiseptic Oromucosal solution Lidocaine hydrochloride 0.90%w/w, Chlorocresol 0.10%w/w, Cetylpyridinium Chloride 0.

Package leaflet: information for the user. OZURDEX 700 micrograms intravitreal implant in applicator dexamethasone

Zofran syrup contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.

Package leaflet: Information for the user. Colecalciferol 3000 IU/ml Oral Solution (colecalciferol)

Package leaflet: Information for the user. Catacrom 2 % w/v Eye Drops, Solution. Sodium cromoglicate

Gyno-Pevaryl Once 150mg vaginal pessary

Package leaflet: Information for the patient UNITED KINGDOM Feldene 5mg/g Gel piroxicam

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Actikerall 5 mg/g mg/g Cutaneous Solution. Fluorouracil + Salicylic acid

Pravat 40 mg tablets. Pravastatin sodium

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

Package leaflet: Information for the user. Lycimor 300 mg Hard Capsules Lymecycline (equivalent to 300mg of tetracycline base)

FASTUM 2.5% gel PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1. WHAT FASTUM GEL IS AND WHAT IT IS USED FOR

Package leaflet: Information for the patient. Olumiant 2 mg film-coated tablets Olumiant 4 mg film-coated tablets Baricitinib

PACKAGE LEAFLET: INFORMATION FOR THE USER. ZADITEN 1 mg/5 ml Oral Solution. Ketotifen (as Ketotifen hydrogen fumarate)

ANDROGEL 50 mg, gel in sachet Testosterone

1g cream or ointment contains 1 mg methylprednisolone aceponate.

Package leaflet: Information for the patient. Valotix 500 mg Film-Coated Tablets Valaciclovir

CONSUMER MEDICINE INFORMATION CLOTRIZONE CREAM

Proposed PIL NL/H/0653/001/IB/024/G. MONOFREE DEXAMETHASON 1 mg/ml, eye drops, solution in single-dose container Dexamethasone phosphate

Package leaflet: Information for the user. Qutenza 179 mg cutaneous patch capsaicin

1. What Octostim Nasal Spray is and what it is used for

PATIENT INFORMATION LEAFLET

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. ILAXTEN 20 MG TABLETS bilastine

THORENS I.U. /2.5 ml oral solution. Cholecalciferol (vitamin D 3 )

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe

2 What you need to know before you use Zofran Suppositories

Package leaflet: Information for the user. Ondansetron 4mg/5ml Syrup (ondansetron as ondansetron hydrochloride dihydrate)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Venaforce Varicose Veins gastro-resistant tablets Horse Chestnut seed dry extract

Dalacin C 150 mg Hard Capsules Clindamycin (as clindamycin hydrochloride)

Package leaflet: Information for the patient

Package leaflet: Information for the patient. Vertigon 8 mg Tablets Vertigon 16 mg Tablets (betahistine dihydrochloride)

PACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Turbohaler budesonide. 1. What Pulmicort Turbohaler is and what it is used for

PACKAGE LEAFLET: INFORMATION FOR THE USER. Tantum Verde orange-honey taste 3 mg lozenges Benzydamine Hydrochloride

IOPIDINE 5mg/ml Eye Drops, solution contain apraclonidine (as hydrochloride) as the active substance.

Package leaflet: Information for the patient. Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets dapagliflozin

Package leaflet: Information for the user Pulmicort Respules 0.5 mg, Nebuliser Suspension budesonide

Package leaflet: Information for the user. Portrazza 800 mg concentrate for solution for infusion necitumumab

PACKAGE LEAFLET: INFORMATION FOR THE USER. Folic Acid 2.5mg/5ml Oral Solution Folic Acid 2.5mg/5ml

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

Package leaflet: Information for the user. <PRODUCT NAME> 10 g powder for oral solution in sachet Macrogol 4000

Package leaflet: Information for the user. <product name> 3 mg/ml eye drops, solution. Ofloxacin

SUMMARY OF PRODUCT CHARACTERISTICS

PACKAGE LEAFLET: INFORMATION FOR THE USER. ANESDERM 25 mg/g + 25 mg/g Cream Lidocaine, Prilocaine

RESOLVE PLUS 1.0 Hydrocortisone, miconazole nitrate

Package leaflet: Information for the user. Calcipotriol/Betamethason Sandoz 50 microgram/g + 0,5 mg/g, zalf calcipotriol/betamethasone

Package leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime

Package leaflet: Information for the user. Xalatan 50 micrograms/ml Eye drops, solution Latanoprost

Atrosan Devil s Claw film-coated tablets

Package leaflet: Information for the user. Sebivo 600 mg film-coated tablets Telbivudine

PACKAGE LEAFLET: INFORMATION FOR THE USER. Budesonide Teva 0.5 mg/2 ml Nebuliser Suspension Budesonide

Package leaflet: Information for the user. GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution Bimatoprost/timolol

Package leaflet: Information for the patient

Package leaflet: Information for the user. Irprestan 150 mg film-coated tablets. Irprestan 300 mg film-coated tablets irbesartan

Transcription:

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Monovo 1 mg/g ointment Mometasone furoate Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Monovo is and what it is used for 2. What you need to know before you use Monovo 3. How to use Monovo 4. Possible side effects 5. How to store Monovo 6. Contents of the pack and other information 1. WHAT MONOVO IS AND WHAT IT IS USED FOR Monovo contains the active substance mometasone furoate, which belongs to a group of medicines called topical corticosteroids (or steroids). Topical corticosteroids can be divided into four degrees of strength or potency: mild, moderate, potent and very potent. Monovo is classified as a potent corticosteroid. In adults, adolescents and children, aged 6 years and older, Monovo is used to reduce symptoms caused by certain inflammatory skin disorders such as psoriasis (excluding widespread plaque psoriasis) and atopic dermatitis. This preparation is generally used to treat very dry, scaly and cracked skin complaints. It is not a cure for your condition, but should help to relieve your symptoms. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE MONOVO Do not use Monovo if you, or your child are allergic to mometasone furoate, or other corticosteroids or any of the other ingredients of this medicine (listed in section 6), on any other skin problems as it could make them worse especially: rosacea (a skin condition affecting the face) acne dermatitis around the mouth (perioral dermatitis) perianal and genital itching nappy rash bacterial infections such as impetigo, viral infections such as cold sores, shingles, and chickenpox (varicella), fungal infections such as athlete s foot (red, itchy, flaky skin on the feet), or thrush (an infection affecting the vagina that can cause discharge and itching)

bacterial infections such as tuberculosis (infection of the lung) or syphilis (a sexually transmitted disease) if you have recently had a reaction to a vaccination (e.g. for flu) on the eyelids Warnings and precautions Talk to your doctor or pharmacist before using Monovo. Monovo should not be put on the eyelids. Take care not to get any ointment in the eye. However if this should occur rinse thoroughly with clean water. If eye irritation remains please see your doctor. The ointment should not be applied to broken skin and mucous membranes. Do not use the ointment on your face without close supervision of your doctor. If irritation or sensitisation develops with the use of Monovo, you should tell your doctor immediately. When this medication is used on psoriasis, it may make the conditions worse (e.g. a pustular form of the disease may occur). You should let your doctor review your progress at regular intervals, as such treatment needs careful supervision. Contact your doctor if you experience blurred vision or other visual disturbances. Children (under 6 years of age) Monovo ointment should not be used in children under 6 years of age. Other medicines and Monovo Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. This includes medicines obtained without a prescription and any other remedies or dietary supplements such as vitamins. Ask your doctor for advice before taking any medicine. Do not use latex products (e.g. condom, diaphragms) together with Monovo in the genital or anal area, as the safety of these products may be impaired. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.if your doctor does prescribe the ointment to you during pregnancy or while you are breast-feeding, you should avoid using large doses and the use should be limited to a short period. Do not apply Monovo to the breast area whilst breast-feeding. Monovo contains propylene glycol monopalmitostearate and emulsifying cetostearyl alcohol. Propylene glycol monopalmitostearate may cause skin irritation. Emulsifying cetostearyl alcohol may cause local skin reactions (e.g. contact dermatitis). 3. HOW TO USE MONOVO Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Your doctor should review your treatment at regular intervals. Adults, including the elderly, adolescents and children 6 years of age and older: A thin layer of ointment should be gently applied to the affected areas of skin once daily. You only need to use a small amount of this preparation. If you have been prescribed the ointment, one fingertip unit (a line from the tip of an adult index finger to the first crease) is enough to cover an area

twice the size of an adult hand. Never apply more than this quantity or more often than advised by your doctor or pharmacist. Adults, including the elderly: You should not use the ointment on large areas of the body (over 20% of body surface area) or for a long time (for example every day for over three weeks). Unless directed by your doctor, do not apply a bandage or dressing to the area being treated. This will increase absorption of the preparation and increase possible side effects. Children (6 years of age and older): Do not use the ointment for children over 6 years of age on any part of their body without close supervision of the doctor. Do not apply the ointment to more than 10% of the child s body surface area. Do not use in skin folds and under airtight dressings. Do not use for more than 3 weeks. Method of administration Monovo ointment is for cutaneous use (use on the skin). This medicinal product is for external use only. If you used more Monovo than you should If you (or somebody else) accidentally swallow the ointment, it should not produce any undesirable effects. However, if you are worried, you should see your doctor or pharmacist. If you use the ointment more often than you should, or on large areas of the body, it can affect some of your hormones. In children, this may affect their growth and development. If you have not followed the dosage instructions or your doctor s advice and have used the ointment too frequently and/or for a long time, you should tell your doctor or pharmacist. If you forget to use Monovo If you forget to apply the ointment at the scheduled time, do it as soon as you remember and then carry on as before. Do not apply twice as much or use twice in one day to make up for a missed application. If you stop using Monovo Do not stop treatment suddenly if you have used it for a long time since this may be harmful. Treatment should be stopped gradually, as advised by your doctor. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4. POSSIBLE SIDE EFFECTS Like all medicines, this medicine can cause side effects, although not everybody gets them. If your symptoms do not begin to improve after using this medicine as instructed by your doctor or if they get worse, check with your doctor. Side effects in children and adults that have been reported with the use of topical corticosteroids include: Common: may affect up to 1 in 10 people These include mild to moderate burning sensations at the application site, tingling/stinging, itching, bacterial infections, abnormal sensations on the skin (paraesthesia), skin boils (furunculosis), and thinning of the skin (skin atrophy).

Uncommon: may affect up to 1 in 100 people These include irregular skin marks or stripes (striae), skin irritation, unusual hair growth (hypertrichosis), changes in skin colour, dermatitis around the mouth (perioral dermatitis), softening and whitening of the skin (maceration), allergic contact dermatitis, pus-filled blisters on facial skin (papulous rosacea-like dermatitis), inflammation (including acne type reactions), purple or dark blue discoloration of the skin (ecchymoses), heat rash (miliaria), dryness, sensitisation, inflammation of skin follicles (folliculitis) and secondary infection. Very rare: may affect up to 1 in 10,000 people Dilated blood vessels on the skin or spider veins. Not known: frequency cannot be estimated from the available data Blurred vision. Increased usage, treatment of large areas of skin, long term use and use under a dressing may increase the risk of side effects. Corticosteroids may affect the normal production of steroids in the body. This is more likely to happen if high doses are being used over a long period of time. Children in particular, treated with corticosteroid ointments and creams can absorb product through the skin and this can lead to a disorder called Cushing s syndrome which includes many symptoms, such as a fat, round face and weakness. Children on long term treatment may grow more slowly than others. Your doctor will help prevent this happening by prescribing the lowest dose of steroid at which your symptoms are wellcontrolled. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, Website: www.hpra.ie, e-mail: medsafety@hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine. 5. HOW TO STORE MONOVO Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and the tube after EXP. The expiry date refers to the last day of that month. This medicine does not require any special storage conditions. Discard the opened tube with any remaining ointment after 6 months. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6. FURTHER INFORMATION What Monovo contains - The active substance is mometasone furoate. One gram of ointment contains 1 mg of mometasone furoate (0.1% mometasone furoate). - The other ingredients are: White soft paraffin, liquid paraffin, 2-methylpentane-2,4-diol, emulsifying cetostearyl alcohol (type A contains disodium/potassium hydrogen phosphate for ph adjustment), propylene glycol monopalmitostearate, white beeswax, purified water, anhydrous citric acid, sodium citrate.

What Monovo looks like and contents of the pack Monovo is an off-white, transparent ointment. The ointment is filled in aluminium tubes fitted with a white plastic screw cap in a cardboard carton. Pack sizes: Tubes with 10 g, 15 g, 20 g, 25 g, 30 g, 35 g, 50 g, 60 g, 70 g, 90 g and 100 g of ointment. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Almirall Hermal GmbH Scholtzstrasse 3 21465 Reinbek Germany Tel: +49 40 727 040 Fax : +49 40 72 704 329 Email: info@almirall.de This medicinal product is authorised in the Member States of the EEA under the following names: Country Austria Germany Ireland Italy Luxembourg Poland Portugal Spain The Netherlands United Kingdom Trade names Monovo 1 mg/g Ointment Frondava 1 mg/g Unguento Ivoxel Ivoxel 1 mg/g Pomade Monovo 1 mg/g Pomada Monovo 1 mg/g Zalf Mometasone furoate 0.1% w/w Ointment This leaflet was last revised in 06/2017